Andreasen TH, et al. - Via independently hunting the databases ClinicalTrials.gov, Embase, Pubmed and Web of Science by two screeners, researchers sought to explore the placebo response in clinical trials assessing the impact of systemic and biological therapies in adult atopic dermatitis (AD) and compared it to outcomes from clinical trials in psoriasis. In total, 2,058 articles have been identified, 78 of which were full-text reviewed. At 12-week follow-up, EASI50, EASI75, and EASI90 placebo responses, respectively, were 39.9%, 20.9%, and 9.0%. Compared with the pooled proportion of placebo-treated psoriasis patients obtaining PASI50, PASI75, and PASI90, the pooled proportion of placebo-treated AD patients obtaining EASI50, EASI75 and EASI90 were significantly higher at week 12. The results obtained from the systematic review and meta-analysis underline the fluctuating nature of AD and demonstrate that correct and consistent use of topical treatments strongly reduces the severity of the disease.